Browse the corpus

Doses up to 7000 mg of bamlanivimab (10 times the FDA recommended dose) or 7000 mg of etesevimab (5 times the FDA recommended dose ) have been studied in clinical trials, which did not show any of the dose-limiting toxicity. If an overdose of bamlanivimab and etesevimab happens, treatment comprises supportive measures, including vitals and clinical status monitoring. As of now, there is no specific antidote available for the overdose.[9]

The interprofessional healthcare team must communicate with the patient, parent, or caregiver and provide a copy of the fact sheet before administering the combination therapy (bamlanivimab and etesevimab). The fact sheet includes the following information: The FDA has approved etesevimab and bamlanivimab for emergency use to treat mild to moderate SARS-CoV-2. It can be used in adults and pediatrics if they are 12 years old and above, weigh 40 kg or more, and are at high risk of progressing to severe COVID-19 or hospitalization. The patient or parent/caregiver has the option to accept or refuse. The potential risks and benefits of medications are unknown. Patients treated with bamlanivimab and etesevimab should follow the CDC guidelines (wear a mask, social distancing, avoid sharing personal items, and frequent handwashing). Etesevimab and bamlanivimab infusion should be given only by a qualified healthcare professional, and the patient should be monitored for anaphylaxis for at least 1 hour after completing the infusion. The healthcare team comprising the physician, nurse practitioner, and nurse is jointly responsible for reporting medication errors and serious adverse events related to etesevimab and bamlanivimab treatment within 7 days from the onset of the event. The Secretary of the HHS (Department of Health and Human Services) has announced a public health emergency that justifies the EUA of etesevimab and bamlanivimab during the SARS-CoV-2 pandemic. This EUA can be terminated when the HHS secretary finds that the situation justifying the EUA no longer exists. When administering this novel therapy, all interprofessional team members must communicate constantly and operate as a functional unit, collaborating and coordinating their activities and information collection. This includes clinicians, specialists, nurses, and pharmacists operating as a cohesive unit to optimize patient outcomes.